28651929Harrington KJ, Ferris RL, Blumenschein G, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay JThe Lancet. OncologyAntibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Neoplasm Recurrence, Local; Quality of LifeAnorexia; Cetuximab; Disease Progression; Docetaxel; Dyspnea; Fatigue; Humans; Kaplan-Meier Estimate; Methotrexate; Nivolumab; Pain; Patient Reported Outcome Measures; Sensation Disorders; Social Participation; TaxoidsNivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1104-1115.Lancet Oncol2017-06-23T00:00:002017Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000970Chemicals & Drugs40723510.435494Antineoplastic AgentsD002294Disorders19910750.588875Carcinoma, Squamous CellD000855Disorders23300.983551AnorexiaD000911Chemicals & Drugs33713760.622785Antibodies, MonoclonalAuthorship 10630180.1564180.1564181authors10.2519has subject areaD004417Disorders49720.942524DyspneaD010146Disorders1983890.803817PainD008727Chemicals & Drugs772490.929424MethotrexateD012678Disorders16230.978955Sensation DisordersD005221Disorders1091740.909607FatigueD006258Disorders15210510.576809Head and Neck NeoplasmsD011788Concepts & Ideas43115750.549294Quality of LifeD006801Living Beings2262862810.130064HumansD009364Disorders33613050.619886Neoplasm Recurrence, LocalD018450Physiology49815310.700876Disease ProgressionD043823Chemicals & Drugs561290.941532TaxoidsD058992Activities & Behaviors12140.983211Social ParticipationD053208Concepts & Ideas3258590.818624Kaplan-Meier EstimateD000068818471130.945058CetuximabD0000710661041650.893853Patient Reported Outcome MeasuresMedicineUniversity of ChicagoEverett E.VokesEverett E. Vokes41.78927490000000-87.601250000000001920Vokes, Everett E.Professortrue1ProfessorProfessor